Early DOlutegravir/LAmivudine Switching After Virological Suppression (EDOLAS Study)

Societa' Italiana Di Malattie Infettive E Tropicali440 enrolled

Overview

Phase III, randomized, open-label, multicentre, active-controlled, non-inferiority study evaluating the efficacy and safety of early switching to dolutegravir/lamivudine (DTG/3TC) in single-pill, in HIV-1 infected individuals currently taking an INSTI-based three-drug first-line regimen for less than 18 months and who have been virologically suppressed with HIV-1 RNA \<50 copies/mL

The target population of this study is HIV-1-infected adults without previous virological failure, currently receiving any first-line, triple-drug ART having an INSTI (EVG/cobi, RAL QD, DTG, BIC) as anchor drug associated to any of the following dual NRTI backbone (ABC/3TC, TDF/FTC or TAF/FTC) with virological suppression (HIV-1 RNA \< 50 copies/mL). Participants will be randomly allocated 1:1 to switch to DTG/3TC 50/300 mg as a single pill qd until week 96 (Arm A, early switch) or to continue their INSTI-based ART triple regimen received at screening (Arm B, delayed switch) until week 52, when participants in Arm B with HIV-1 RNA\< 50 cp/mL at week 48 will switch to DTG/3TC 50/300 mg qd as a single pill until week 100. The drugs of both arms will be administered in an open-label manner throughout the entire duration of the study. The primary analysis will take place after the last participant completes 52 weeks on therapy, to allow for the collection of a confirmatory viral load measurement in participants possibly presenting with HIV-1 RNA ≥50 cp/mL at the Week 48 visit. If the second determination of HIV-1 RNA is \<50 cp/mL, then the participant has not a virological rebound and will be considered eligible to switch to DTG/3TC at Week 52. If the second determination of HIV-1 RNA is ≥50 cp/mL, then the participant will be considered protocol-defined virological failure, thus being ineligible to switch to DTG/ 3TC. These participants will be withdrawn from the study. A preliminary interim analysis will be performed after 50% of the enrolled participants have reached the 24th week of study, always considering 4 weeks more (thus 28 weeks) to allow for the collection of a confirmatory viral load measurement in participants possibly presenting with HIV-1 RNA ≥50 copies/mL at Week 24. At week 48, participants in Arm A (early switch) will continue DTG/3TC. At week 52, participants in Arm B (delayed switch) and with HIV-1 RNA \< 50 copies/mL at week 48 will switch to DTG/3TC and will be followed until week 100. The exploratory analyses at Week 96 will take place after the last participant completes 100 weeks on therapy, as needed, to allow for the collection of a confirmatory viral load measurement in participants presenting with HIV-1 RNA ≥50 copies/mL at Week 96.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

OTHER

Masking

NONE

Enrollment

440

Conditions

HIV-1-infection

Interventions

DOVATODRUG

Dovato is a medicine for treating infection with human immunodeficiency virus type 1 (HIV-1), a virus that causes acquired immune deficiency syndrome (AIDS).

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * HIV-1 documented infection; * Aged 18 years or older at the time of signing the informed consent; * Stable INSTI-based first-line three-drug ART (switch between different NRTIs are allowed; e.g. from TDF/FTC to TAF/FTC or ABC/3TC, from TAF/FTC to TDF/FTC or ABC/3TC, from ABC/3TC to TAF/FTC or TDF/FTC). Any change of INSTI will not be allowed. Only the following regimens will be allowed: * RAL 1200 mg QD plus TDF/FTC or TAF/FTC; * RAL 1200 mg QD plus ABC/3TC; * EVG/COBI/FTC/TDF or EVG/COBI/FTC/TAF; * DTG plus TDF/FTC or TAF/FTC; * DTG/ABC/3TC or DTG plus ABC/3TC; * BIC/TAF/FTC * Previous INSTI-based first-line ART lasting less than 18 months before screening; * To have reached a HIV-1 RNA \<50 copies/mL during INSTI first-line therapy for less than 12 months. At least a single HIV-1 RNA determination below the threshold within the 6 months before enrollment is required (if a following determination in present, this should not be ≥50 copies (cp)/mL) * HIV-1 RNA below 50 copies/mL at the screening visit; * No known allergy or intolerance to the study drugs or their components or drugs of their class; * A female person is eligible to enter the study if it is confirmed that she is: * Not pregnant confirmed by a negative serum pregnancy test at both Screening and Day1; * Not breastfeeding; * Of non-childbearing potential defined as either post-menopausal (12 months of spontaneous amenorrhea and ≥45 years of age) or physically incapable of becoming pregnant with documented tubal ligation, hysterectomy or bilateral oophorectomy; * Of childbearing potential and agrees to utilize the protocol specified method of contraception (as defined in Appendix 1 -Highly Effective Methods for Avoiding Pregnancy in Females of Reproductive Potential) or be non-heterosexually active or practice sexual abstinence (defined as complete abstinence from penile-vaginal intercourse; periodic abstinence, e.g. calendar, ovulation, symptothermal, post-ovulation methods and withdrawal are not acceptable methods of contraception) from screening throughout the duration of study treatment and for at least two weeks following discontinuation of study drugs; * Being able to comply with the protocol requirements and restrictions; * Signature of written Informed Consent Form (participants or legal guardian) before that any protocol-specified assessments are conducted. Exclusion Criteria: A person will be considered not eligible for inclusion in this study if any of the following criteria apply: * Having failed virologically; * Having changed the INSTI drug; * Any major INSTI- or NRTI-resistance-associated mutation documented before starting ART; * Women who are pregnant or breastfeeding or plan to become pregnant or breastfeed during the study; * Evidence of Hepatitis B virus (HBV) infection based on the results of testing at screening for hepatitis B surface antigen (HBsAg), hepatitis B core antibody (anti-Hbc), hepatitis B surface antigen antibody (anti-HBs) and, possibly, HBV DNA as follows: * Individuals positive for HBsAg are excluded; * Individuals negative for anti-HBs but positive for anti-HBc (negative HBsAg status) and positive for HBV DNA are excluded; * HCV-RNA positivity needing for any hepatitis C virus (HCV) therapy during the study; * Ongoing malignancy other than cutaneous Kaposi's sarcoma (not requiring systemic therapy), basal cell carcinoma, or resected, non-invasive cutaneous squamous cell carcinoma, or cervical, anal or penile intraepithelial neoplasia; * Active opportunistic infections requiring active treatment; * Creatinine clearance of \<50 mL/min/1.73m2 via CKD-EPI method; * Individuals with severe hepatic impairment (Child Pugh class C) and/or unstable liver disease; * Any verified Grade 4 laboratory abnormality at screening assessment; * Alanine aminotransferase (ALT) \>5 times the upper limit of normal (ULN) or ALT \>3xULN and bilirubin \>1.5xULN (with \>35% direct bilirubin) at screening assessment; * Receipt of investigational research agents within 30 days prior to study entry; * Treatment with an HIV-1 immunotherapeutic vaccine within 90 days of screening; * Receipt of immunosuppressive medications or immune-modulators within the past 6 months; * Individuals who in the investigator's judgment, poses a significant suicidality risk or with diagnosed major depression, Bipolar Disorders and Psychoses * A life expectancy estimated as less than 2 years.

Locations (25)

Outcomes

Primary Outcomes

Non-inferior efficacy of switching

Proportion of participants with virological rebound (viral load ≥50 copies/mL or premature discontinuations, irrespective of reason, with last viral load ≥50 copies/mL) at week 48

Time frame: 48 weeks

Secondary Outcomes

Efficacy of switching

Proportion of participants with HIV-1 RNA \<50 copies/mL at week 48 (FDA Snapshot algorithm)

Time frame: 48 weeks

Safety and tolerability

Clinical and laboratory safety parameters; a descriptive analysis of all reported AEs and a quantitative analysis of AEs leading to treatment interruption/change will be used to evaluate long-term tolerability of the simplification treatment.

Time frame: 100 weeks

Immunologic response and dysfunction

Changes in CD4+ and CD8+ T-lymphocyte counts (absolute and percentage), and in CD4+/CD8+ ratio (as a measure of immune activation) in the peripheral blood from baseline to week 48 and 96.

Time frame: 100 weeks

Emergent drug resistance-associated mutations

Proportion of participants developing resistance-conferring mutations (to any drug class) by genotypic resistance test (GRT) in plasma or proviral DNA (in case of low viremia levels, \<200 copies/mL) at protocol-defined virological failure (PDVF) will be cumulatively described throughout the study period.

Time frame: 100 weeks

RT and INSTI resistance-associated mutations

iral minority variants harboring resistance associated mutations (to any drug class) at the time of PDVF will be characterized in plasma or in proviral DNA (in case of low viremia levels, \<200 copies/mL) by next generation sequencing. For the minority resistant variants detected (prevalence \>1%), their resistance viral burden will be also evaluated.

Central Contacts

Andrea Antinori, P.I.

CONTACT

0655170546 andrea.antinori@inmi.it

Maddalena Plazzi, DM

CONTACT

3384093449 maria.plazzi@inmi.it

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.